What's Happening

Stay up to date on pharmaceutical developments, industry issues, and what’s happening with Healthesystems

Events

Healthesystems’ conferences and speaking engagements

WCI Annual Conference

August 21-24, 2022 in Orlando Florida

Visit Healthe in booth #913 to learn more about our workers’ comp pharmacy & ancillary benefits

National Comp (NWCD Conference)

October 19-21, 2022 Las Vegas, Nevada

Visit Healthe in booth #621 to participate in our Annual Industry Survey for a chance to win $500

Attend our VP of Clinical Services, Dr. Silvia Sacalis’ session on Thursday 10/20 @ 2pm: “Building an Employee Culture of Well-Being and Trust Amid COVID and Beyond”

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets

Approval Date: Aug 2022

Note: New Product

For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week

hello world!

Synjardy® (empagliflozin and metformin hydrochloride) tablets

Approval Date: Jul 2022

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

hello world!

Edarbi® (azilsartan medoxomil) tablets

Approval Date: Jul 2022

Note: First-Time Generic

Indicated for the treatment of hypertension to lower blood pressure

hello world!

Nalfon® (fenoprofen calcium) tablets

Approval Date: Jul 2022

Note: First-Time Generic

An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis

hello world!

Zoryve (roflumilast) cream

Approval Date: Jul 2022

Note: New Product

Indicated for topical treatment of plaque psoriasis

hello world!

Zonisade (zonisamide) oral suspension

Approval Date: Jul 2022

Note: New Dosage or Formulation

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

hello world!

Briviact (brivaracetam) tablets

Approval Date: Jun 2022

Note: First-Time Generic

Indicated for the treatment of partial-onset seizures.

hello world!

Riabni (rituximab-arrx)

Approval Date: Jun 2022

Note: New Indication

A biosimilar to Rituxan® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.

hello world!

Skyrizi® (risankizumab-rzza) injection

Approval Date: Jun 2022

Note: New Indication

Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.

hello world!

Vtama® (tapinarof) cream

Approval Date: May 2022

Note: New Product

A steroid-free topical indicated for treatment of plaque psoriasis

hello world!
1 2 3 7

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmenucross-circle